Table 3.
Cytokines | HCs | RA | p value (HCs vs RA) |
---|---|---|---|
IL-10%/CD4+CD25−Foxp3+ T cells | 28.33 (15.20–36.53) | 29.43 (18.72–43.84) | 0.651 |
IL-10%/CD4+CD25+Foxp3+ Treg cells | 21.69 (16.48–28.50) | 20.36 (13.34–33.86) | 0.778 |
IL-10%/CD4+CD25+Foxp3− effector T cells | 21.25 (15.22–29.93) | 15.24 (11.20–25.51) | 0.254 |
IL-17A% /CD4+CD25−Foxp3+ T cells | 3.20 (1.85–5.51)† | 6.19 (3.94–8.12) | 0.048 |
IL-17A%/CD4+CD25+Foxp3+ Treg cells | 2.62 (1.58–5.36) | 6.18 (5.03–13.34) | 0.009 |
IL-17A% /CD4+CD25+Foxp3− effector T cells | 14.98 (8.58–19.07) | 7.76 (5.27–20.07) | 0.334 |
IFN-γ %/CD4+CD25−Foxp3+ T cells | 9.87 (4.61–11.20)*† | 10.34 (5.96–16.54)*† | 0.651 |
IFN-γ%/CD4+CD25+Foxp3+ Treg cells | 2.96 (1.57–4.28) | 3.72 (2.73–5.73) | 0.395 |
IFN-γ%/CD4+CD25+Foxp3− effector T cells | 3.62 (3.54–4.32) | 6.83 (3.44–12.66) | 0.279 |
All the data were demonstrated as median [IQR, 25th-75th percentile]
HCs, healthy controls; RA, rheumatoid arthritis; IL-10, interleukin 10; IL17-A, interleukin 17A; IFN-γ, interferon gamma
*Indicates significance (p < 0.05) compared with CD4+CD25 +Foxp3+ Treg cells in RA group or HCs
†Indicates significance (p < 0.05) compared with CD4+CD25+Foxp3− effector T cells in RA group or HCs